Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of PainTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the publication of ...

TORONTO and GLIL YAM, Israel, Jan. 26, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced that it has raised a total of US$2,171,660.40 in debt financings from an arm's length third party (the "Lender") in order to manage the Company's current liquidity requirements. First Note Pursuant to a note purchase agreement between the Company and Lender dated January 7, 2026 (the "First Note Purch ...

Core Insights - IM Cannabis Corp. has appointed Mr. Alon Dayan to its board of directors effective December 31, 2025, enhancing its leadership team with expertise in technology and business development [1][2]. Company Overview - IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [3]. - The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain, aiming to amplify its commercial and brand power in the global cannabis market [3]. Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [4]. - The company also runs medical cannabis retail pharmacies and online platforms in Israel to ensure safe delivery and quality control of its products throughout the value chain [4]. - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [4].

Company Overview - Tilray Brands, Inc. (NASDAQ:TLRY) is a Canadian lifestyle consumer products company specializing in medical cannabis products, operating through four segments: Beverage, Cannabis, Distribution, and Wellness [4]. Analyst Sentiment - As of December 24, slightly more than 60% of analysts covering Tilray Brands assigned a Hold rating, while 36% recommended buying the stock [1]. - Bernstein analyst Nadine Sarwat reiterated a 'Market Perform' rating on December 22, significantly raising the price target from $1 to $10 [2]. Price Target and Potential - The target price for Tilray Brands ranges from $8.50 to $25, with a median price target of $19, indicating an upside potential of 88.49% [1]. Market Trends - Cannabis has emerged as a bipartisan issue, with 64% of Americans in favor of cannabis legalization by 2025, although this is a decrease from the 70% peak reported in 2023 [4]. - President Trump's cannabis-related Executive Order aims to reschedule cannabis from Schedule I to III and revise the statutory definition of hemp-derived cannabinoid products, which could accelerate research and establish a regulatory approach [3].

Core Viewpoint - The potential rescheduling of marijuana under the Controlled Substances Act in the U.S. could enhance legal clarity for patients traveling from Colombia with prescribed medical cannabis and may impact international trade and policy for compliant pharmaceutical suppliers [1]. Group 1: Legal Implications - The ongoing U.S. federal process to reschedule marijuana may lead to improved legal clarity for medical cannabis patients [1]. - Changes in the legal status of marijuana could affect the compliance requirements for pharmaceutical suppliers operating in the medical cannabis sector [1]. Group 2: International Trade - The rescheduling of marijuana could have significant implications for international trade, particularly for countries like Colombia that are involved in the medical cannabis industry [1]. - Colombian medical cannabis operators, such as Sannabis S.A.S., may benefit from clearer regulations that facilitate cross-border transactions [1].

Core Viewpoint - Vireo Growth Inc. plans to acquire additional senior secured convertible notes of Medicine Man Technologies Inc. (Schwazze) at a significant discount, indicating a strategic move to strengthen its financial position and market presence [1][2]. Group 1: Acquisition Details - The total outstanding principal plus accrued interest of the acquired notes is approximately $2.6 million, with Vireo acquiring them for about $1.6 million, payable in subordinate voting shares at a price of $0.54 per share [1]. - Upon closing, Vireo will have acquired approximately 89% of the outstanding senior secured convertible notes of Schwazze, subject to customary conditions and necessary approvals [2]. Group 2: Company Background - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on building a disciplined and strategically aligned platform in the industry [3]. - The company emphasizes a long-term mindset and a commitment to its customers, employees, shareholders, and the communities it serves, aiming to leverage its national portfolio while maintaining a strong local market focus [3].

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development, clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [3][6] R&D and Clinical Development - Avicanna has established a robust scientific platform leading to the commercialization of over thirty proprietary, evidence-based products, including a diverse range of cannabinoid formulations [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, enhancing patient access and support programs [6][9] - The MyMedi.ca platform aims to improve the medical cannabis patient journey, offering bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company is developing a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Avicanna's active pharmaceutical ingredients are supplied by its subsidiary, ensuring a reliable source of high-quality CBD, THC, and CBG for various applications [9]

Core Insights - Tilray Medical is set to enhance its U.S. medical cannabis operations following federal cannabis rescheduling, indicating a significant shift in the healthcare landscape [1][2] - The formation of Tilray Medical USA, Inc. reflects the company's commitment to innovation and growth in the medical cannabis sector [1][4] Regulatory Developments - The rescheduling of cannabis by President Trump is viewed as a necessary evolution of U.S. federal policy, aligning regulation with scientific and medical data supporting cannabis use [2] - This regulatory change is expected to create a more credible foundation for medical cannabis research and clinical development, facilitating an integrated state-federal medical cannabis framework [2] Company Strategy and Operations - Tilray Medical has established a strong presence in regulated medical cannabis markets globally, offering over 200 registered products and serving over 500,000 patients [3] - The company plans to expand collaborations with healthcare operators and medical professionals, ensuring compliance with emerging regulatory guidelines [4] - Tilray Medical USA aims to introduce medical-grade cannabis products based on real-world data and insights from international operations [4] Market Position and Expertise - With a mature compliance infrastructure and deep scientific expertise, Tilray Medical is well-positioned to adapt to regulatory changes while maintaining high standards of patient safety and operational integrity [4] - The company has dedicated years to developing the necessary infrastructure and regulatory skills to operate responsibly in federally legal medical cannabis markets [2][3]

Company Overview - Tilray Brands, Inc. is a lifestyle consumer products company involved in the research, cultivation, processing, and distribution of medical cannabis products across various regions including Canada, the United States, Europe, the Middle East, and Africa [2] - At its peak, Tilray's share price reached nearly $150, symbolizing the cannabis boom and attracting significant market interest as a high-growth stock [2] Current Financial Status - As of December 18th, Tilray's share was trading at $12.88, with a trailing P/E ratio of 57.50 [1] - The company has experienced a dramatic decline of approximately 99%, with its current share price around $1.30 and a market capitalization of about $1.5 billion [3] Industry Challenges - Tilray's challenges reflect broader issues within the cannabis sector, including heavy dependence on state and federal regulations, rapidly changing consumer preferences, and competition in markets with limited competitive advantages [4] - The cannabis industry faces a mix of legal and illegal competition, which restricts individual companies' control over their growth trajectories [4] - Political decisions, fleeting popularity cycles, and reliance on pricing as a key differentiator contribute to a challenging operating environment, making it difficult to achieve sustainable long-term shareholder value [4] Investment Risks - While there is potential for profit in Tilray or other cannabis stocks, the inherent volatility, regulatory uncertainty, and structural weaknesses present exceptionally high risks [5] - Investors seeking consistent and durable returns are unlikely to find these qualities in Tilray, as the company's fundamentals have shown the fragility of growth driven by market hype [5] - Tilray serves as a cautionary example for investors focused on long-term capital preservation, highlighting the dangers of pursuing market trends in sectors with limited control over outcomes [5]

Core Insights - MediPharm Labs Corp. has completed its first shipment of pharmaceutical-grade cannabis products to France, marking its entry into the European medical cannabis market [1][2] - The French medicinal cannabis market is projected to grow from US$187.6 million in 2025 to US$213.3 million by 2030, indicating significant potential for the company [2] - As of Q3 2025, international medical cannabis accounted for 56% of MediPharm's total revenue, with an 83% year-over-year growth in this segment [2] Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [4] - The company operates a Good Manufacturing Practices certified facility and has invested in advanced technology and research-driven teams to ensure high-quality product delivery [4] - MediPharm Labs holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale domestic GMP License for cannabinoid extraction [5] Strategic Partnerships and Expansion - The recent shipment to France follows a production agreement with an international medicinal cannabis organization, enhancing MediPharm's reputation as a trusted supplier [2] - The company has established distribution and supply partnerships globally, now shipping products to 10 countries [3] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [6]